Report: Gilead Struggling to Find Subjects for COVID-19 Drug Trial

Gilead Sciences (NASDAQ: GILD) appears to have hit another roadblock in its race to defeat COVID-19. The company is reportedly having trouble recruiting enough test subjects for its clinical trial of a drug candidate to fight the coronavirus.

According to an article published Tuesday in The Wall Street Journal, Gilead had intended to involve nearly 800 COVID-19 patients in the trial taking place in Wuhan, China, the city at the epicenter of the disease's outbreak. However, the company has only been able to sign up 185 people who qualify. Of those volunteers, 168 presented with severe symptoms, while the remainder presented with moderate or mild ones.

Image source: Getty Images

Source Fool.com